REPO-HFPEF II, a Phase IIa clinical study in patients with heart failure with preserved ejection fraction, has finalized enrolling its last patient. The trial, which investigates a triple combination of three drugs approved for other therapeutic uses (the pulmonary hypertension drug, vericiguat; the amino acid, L-citrulline; and the vitamin, folic acid) on top of standard therapy, includes now 21 patients. REPO-HFPEF II is part of REPO-TRIAL, a 5.5-year project funded by a Horizon 2020 research grant (No. 777111) from the European Commission. Read the entire press release.